
CORDANI NICOLETTA
Pubblicazioni
Cazzaniga, M., Pepe, F., Rossi, E., Coltelli, L., Beano, A., Valerio, M., et al. (2025). A Phase 2, open label, multicenter, single arm trial evaluating the activity and safety of Abemaciclib + Aromatase Inhibitors (AIs) as second-line treatment after first-line Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-factor-Receptor-negative (HER2-) metastatic breast cancer (MBC) patients. Final results of HERMIONE-7 trial. CLINICAL BREAST CANCER [10.1016/j.clbc.2025.05.003]. Dettaglio
Malighetti, F., Villa, M., Villa, A., Pelucchi, S., Aroldi, A., Cortinovis, D., et al. (2025). Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 26(5) [10.3390/ijms26051943]. Dettaglio
Duranti, E., Cordani, N., Villa, C. (2024). Edaravone: A Novel Possible Drug for Cancer Treatment?. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 25(3 (February 2024)) [10.3390/ijms25031633]. Dettaglio
Villa, M., Malighetti, F., Sala, E., Sharma, G., Arosio, G., Gemelli, M., et al. (2024). New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients. NPJ PRECISION ONCOLOGY, 8(1) [10.1038/s41698-024-00498-w]. Dettaglio
Malighetti, F., Villa, M., Sala, E., Geeta, G., Arosio, G., Gemelli, M., et al. (2024). Abstract 987: Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy. Intervento presentato a: American Association for Cancer Research Annual Meeting 2024 - April 5-10, 2024, San Diego, CA [10.1158/1538-7445.am2024-987]. Dettaglio
Premi e responsabilità scientifiche
Premi
- Fondazione Veronesi Post-Doctoral Fellowship, Fondazione Umberto Veronesi, 2019
- Fondazione Veronesi Post-Doctoral Fellowship, Fondazione Umberto Veronesi, 2016
Partecipazioni scientifiche
- Fellow - FONDAZIONE UMBERTO VERONESI (Italia), 2019 - 2020
- Fellow - FONDAZIONE UMBERTO VERONESI (Italia), 2016 - 2017
Incarichi di insegnamento o ricerca
- Ricercatore universitario a t.d. - Università degli Studi di MILANO-BICOCCA, 2024 - 2027